Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation — Stella

Recruiting

Back to Acute Myeloid Leukemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

City of Hope Medical Center, Duarte, California

Moffitt Cancer Center, Tampa, Florida

Key details

Phase

Safety & dosing

Sponsor

City of Hope Medical Center

Collaborators

National Cancer Institute (NCI)

Enrollment target

~35 participants

Started

July 2019

Primary completion

January 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov